Cited by 107Adrenal and Paraganglionic TumorsMedical Imaging Techniques and ApplicationsNeuroendocrine Tumor Research Advances

11C-Metomidate PET imaging of adrenocortical cancer

Khan, Tanweera S., Sundin, Anders, Juhlin, Claes, Långström, Bengt, Bergström, Mats, Eriksson, Barbro·2003·European Journal of Nuclear Medicine and Molecular Imaging

Abstract

The diagnostic potential of positron emission tomography (PET) with carbon-11 metomidate in patients with adrenocortical cancer (ACC) was evaluated. Thirteen PET examinations were performed in 11 patients with CT-detected primary tumours or recurrence and/or metastases from a previously histopathologically proven ACC. The findings at PET were compared with those at CT and verified by histopathology. Six studies (group A) were performed in patients who at the time of imaging were free of medication that could interfere with 11beta-hydroxylase activity and thereby tracer uptake at PET, such as adrenal steroid inhibitors or chemotherapy. The remaining seven studies (group B) were carried out in patients who were monitored during treatment with one or a combination of these drugs. PET visualised all viable tumours with high tracer uptake, and revealed two more lesions than were seen on CT. Three necrotic tumours were detected as false negative observations, as confirmed at surgery and histopathological examination. A true negative observation was obtained at PET in the case of a suspected liver metastasis on CT that was found to have fat vacuolation at histopathological examination of an ultrasonically guided core biopsy specimen. Group A showed apparently higher uptake in normal tissues than group B (adrenal, P=0.03; liver, P=0.01). The metomidate uptake was increased in tumour lesions as compared with normal tissues (adrenal, P=0.02; liver, P=0.005). ACC could be clearly visualised with (11)C-metomidate PET except when the tumour was necrotic. Medication with adrenal steroid inhibitors and chemotherapy decreased the tracer uptake.

Integrity signals

Registry

Crossref · 10.1007/s00259-002-1025-9

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • [11C]MTO PET cannot distinguish benign from malignant adrenocortical lesions.

    “It cannot, however, distinguish benign from malignant adrenocortical lesions.”

    From Adrenocortical carcinoma (2014) · cites this paper as [113]

  • [11C]MTO PET can distinguish tumors of adrenocortical origin from noncortical lesions.

    “[11C]MTO PET can distinguish tumors of adrenocortical origin from noncortical lesions (113).”

    From Adrenocortical carcinoma (2014) · cites this paper as [113]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Khan, T. S., Sundin, A., Juhlin, C., Långström, B., Bergström, M., & Eriksson, B.
Affiliations
  • Uppsala University Hospital (SE)
  • Uppsala University (SE)
Corresponding author
Eriksson, Barbro
Venue
European Journal of Nuclear Medicine and Molecular Imaging
Published
2003-03
Volume
30
Issue
3
Pages
403-410
ISSN
  • 1619-7070 (ISSN-L)
  • 1619-7089
OpenAlex
W2008345499
Cited by
107
References
17
Citations by year
2026: 1 · 2025: 2 · 2024: 4 · 2023: 2 · 2022: 5 · 2021: 7 · 2020: 2 · 2019: 2 · 2018: 2 · 2017: 2 · 2016: 6 · 2014: 3 · 2013: 7 · 2012: 7
FWCI
5.45
Type
journal article
Language
en
Open access
closed
Locations
  • European Journal of Nuclear Medicine and Molecular Imaging (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
  • Health Sciences › Medicine › Epidemiology › Neuroendocrine Tumor Research Advances
Keywords
adrenocortical carcinoma, positron emission tomography, tumor necrosis, liver metastasis, cancer detection
MeSH terms
Adrenal Cortex Neoplasms, Adult, Aged, Antineoplastic Agents, Carbon Radioisotopes, Etomidate, Female, Humans, Male, Metabolic Clearance Rate, Middle Aged, Organ Specificity, Sensitivity and Specificity, Tissue Distribution, Tomography, Emission-Computed, Reproducibility of Results, Radiopharmaceuticals

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review